Neil J Wimmer1,2, Alyssa B Dufour3,4,5, Kelly Cho3,4,6, David R Gagnon2,3, Lien Quach2,3,7, Samantha Ly1, Jacquelyn-My Do1, Simon Ostrowski1, J Michael Gaziano1,2,3,4, David P Faxon1,2,4, Scott Kinlay1,2,4. 1. Cardiovascular Division, VA Boston Healthcare System, Boston, Massachusetts. 2. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. MAVERIC, VA Boston Healthcare System, Boston, Massachusetts. 4. Harvard Medical School, Department of Medicine, Boston, Massachusetts. 5. Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts. 6. Division of Ageing, Brigham and Women's Hospital, Boston, Massachusetts. 7. University of Massachusetts, Department of Gerontology, Boston, Massachusetts.
Abstract
OBJECTIVES: To assess the impact of stent type on the risk of death or myocardial infarction (MI) related to dual antiplatelet therapy (DAPT) more than 12 months (prolonged DAPT) versus 12 or less months after PCI for an acute coronary syndrome (ACS). BACKGROUND: The recent DAPT study reported lower recurrent ischemic events from prolonged DAPT in patients treated with PCI for an ACS, but was underpowered to determine the impact of stent type. METHODS: We determined clinical outcomes after PCI for an ACS (median follow-up: DES = 26 months, BMS = 46 months) in 18,484 patients in the Veterans Affairs system treated with first generation drug-eluting stents (DES) or bare-metal stents (BMS). We used landmark analyses starting 1 year after the index PCI to assess the risk of prolonged DAPT on the primary endpoint of death or MI. Multivariable and propensity models adjusted for confounding. RESULTS: There was a significant interaction between stent type and prolonged DAPT for death and MI (P = 0.0036), death (P = 0.054), and major bleeding (P = 0.0013). Patients treated with prolonged DAPT had lower risks of death or MI (HR = 0.71, 95% CI = 0.61, 0.82) and death (HR = 0.74, 95%CI = 0.62, 0.89) with DES, but not BMS, and higher risks of major bleeding, particularly with BMS (HR = 1.67, P < 0.001) than DES (HR = 1.24, p = 0.01). CONCLUSIONS: Prolonging DAPT more than 12 months after PCI for ACS only associated with a lower risk of ischemic events in the 1-4 years after PCI in those receiving first generation DES. Stent type may influence the benefit of prolonged DAPT.
OBJECTIVES: To assess the impact of stent type on the risk of death or myocardial infarction (MI) related to dual antiplatelet therapy (DAPT) more than 12 months (prolonged DAPT) versus 12 or less months after PCI for an acute coronary syndrome (ACS). BACKGROUND: The recent DAPT study reported lower recurrent ischemic events from prolonged DAPT in patients treated with PCI for an ACS, but was underpowered to determine the impact of stent type. METHODS: We determined clinical outcomes after PCI for an ACS (median follow-up: DES = 26 months, BMS = 46 months) in 18,484 patients in the Veterans Affairs system treated with first generation drug-eluting stents (DES) or bare-metal stents (BMS). We used landmark analyses starting 1 year after the index PCI to assess the risk of prolonged DAPT on the primary endpoint of death or MI. Multivariable and propensity models adjusted for confounding. RESULTS: There was a significant interaction between stent type and prolonged DAPT for death and MI (P = 0.0036), death (P = 0.054), and major bleeding (P = 0.0013). Patients treated with prolonged DAPT had lower risks of death or MI (HR = 0.71, 95% CI = 0.61, 0.82) and death (HR = 0.74, 95%CI = 0.62, 0.89) with DES, but not BMS, and higher risks of major bleeding, particularly with BMS (HR = 1.67, P < 0.001) than DES (HR = 1.24, p = 0.01). CONCLUSIONS: Prolonging DAPT more than 12 months after PCI for ACS only associated with a lower risk of ischemic events in the 1-4 years after PCI in those receiving first generation DES. Stent type may influence the benefit of prolonged DAPT.
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: Dean J Kereiakes; Robert W Yeh; Joseph M Massaro; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Anthony H Gershlick; Harald Darius; Ian T Meredith; John Ormiston; Jean Francois Tanguay; Stephan Windecker; Kirk N Garratt; David E Kandzari; David P Lee; Daniel I Simon; Adrian Corneliu Iancu; Jaroslaw Trebacz; Laura Mauri Journal: JAMA Date: 2015-03-17 Impact factor: 56.272
Authors: Martine Gilard; Paul Barragan; Arif A L Noryani; Hussam A Noor; Talib Majwal; Thomas Hovasse; Philippe Castellant; Michel Schneeberger; Luc Maillard; Erwan Bressolette; Jaroslaw Wojcik; Nicolas Delarche; Didier Blanchard; Bernard Jouve; Olivier Ormezzano; Franck Paganelli; Gilles Levy; Joël Sainsous; Didier Carrie; Alain Furber; Jacques Berland; Oliver Darremont; Hervé Le Breton; Anne Lyuycx-Bore; Antoine Gommeaux; Claude Cassat; Alain Kermarrec; Pierre Cazaux; Philippe Druelles; Raphael Dauphin; Jean Armengaud; Patrick Dupouy; Didier Champagnac; Patrick Ohlmann; Knut Endresen; Hakim Benamer; Robert Gabor Kiss; Imre Ungi; Jacques Boschat; Marie-Claude Morice Journal: J Am Coll Cardiol Date: 2014-11-16 Impact factor: 24.094
Authors: Stefanie Schulz-Schüpke; Robert A Byrne; Jurrien M Ten Berg; Franz-Josef Neumann; Yaling Han; Tom Adriaenssens; Ralph Tölg; Melchior Seyfarth; Michael Maeng; Bernhard Zrenner; Claudius Jacobshagen; Harald Mudra; Eberhard von Hodenberg; Jochen Wöhrle; Dominick J Angiolillo; Barbara von Merzljak; Nonglag Rifatov; Sebastian Kufner; Tanja Morath; Antonia Feuchtenberger; Tareq Ibrahim; Paul W A Janssen; Christian Valina; Yi Li; Walter Desmet; Mohamed Abdel-Wahab; Klaus Tiroch; Christian Hengstenberg; Isabell Bernlochner; Marcus Fischer; Heribert Schunkert; Karl-Ludwig Laugwitz; Albert Schömig; Julinda Mehilli; Adnan Kastrati Journal: Eur Heart J Date: 2015-01-23 Impact factor: 29.983
Authors: Arun K Thukkani; Kush Agrawal; Lillian Prince; Kyle J Smoot; Alyssa B Dufour; Kelly Cho; David R Gagnon; Galina Sokolovskaya; Samantha Ly; Sara Temiyasathit; David P Faxon; J Michael Gaziano; Scott Kinlay Journal: J Am Coll Cardiol Date: 2015-09-08 Impact factor: 24.094
Authors: Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Michael J Attubato; Frederick Feit; Deepak L Bhatt; James Slater Journal: Circulation Date: 2012-05-14 Impact factor: 29.690
Authors: Scott Kinlay; Lien Quach; Jean Cormack; Natalie Morgenstern; Ying Hou; Melissa Young; Rebecca Sherrod; Kelly Cho; David P Faxon; Ronnie Ramadan; Michael Gaziano; David Gagnon Journal: J Am Heart Assoc Date: 2021-04-26 Impact factor: 6.106